$1.70
▲ +0.1% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Aldeyra Therapeutics Seeks FDA Clarification on Reproxalap NDA Meeting Minutes
CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Overview
52-week range
$1.07
$6.17
12% of range
Avg surprise (last 3)
+36.6%
Avg reaction (last 2)
+1.9%
50% positive
Latest IV / EM
4631%
EM ±273.5% · $2 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.06 | $-0.13 | +53.9% | +64.7% | -0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.13 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.16 | $-0.21 | +23.8% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.17 | $-0.25 | +32.0% | — | +4.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.25 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.28 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.14 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.14 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.15 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.11 | -$0.16 | +31.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-4M | — | $-8M | $-10M | $-10M | — | $-16M | $-18M |
| Net income | $-3M | — | $-8M | $-10M | $-10M | — | $-15M | $-17M |
| EPS (diluted) | $-0.06 | — | $-0.13 | $-0.16 | $-0.17 | — | $-0.25 | $-0.28 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | $59M | $41M | $50M | $55M | $68M | $71M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $66M | $72M | $77M | $85M | $93M | $104M | $117M | $126M |
| Total assets | $66M | $72M | $78M | $85M | $93M | $105M | $117M | $126M |
| Long-term debt | $0 | $0 | $0 | $0 | $15M | $15M | $15M | $0 |
| Total liabilities | $24M | $28M | $29M | $30M | $30M | $34M | $32M | $28M |
| Total equity | $42M | $44M | $49M | $55M | $64M | $71M | $85M | $98M |